Epigenetic Activation of LncRNA MIR155HG Mediated by Promoter Hypomethylation and SP1 is Correlated with Immune Infiltration in Glioma

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2022 Mar 18

PMID 35299997

Authors

Xuechao Wu

Quan Wan

Jing Wang

Peng Hou

Qijian Zhang

Qing Wang

Xiaojie Lu

Affiliations

Soon will be listed here.

Abstract

Purpose: The lncRNA MIR155 host gene (MIR155HG) plays a role in the progression of several malignant cancers. However, the specific mechanisms of MIR155HG in glioma progression have not been clearly established. The purpose of this study was to investigate the function of MIR155HG in glioma at the transcriptome level and relationship with immune infiltration.

Patients And Methods: Totally, 697 RNA-seq and 594 DNA methylation data were retrieved from The Cancer Genome Atlas (TCGA) dataset while 325 RNA-seq data were retrieved from the Chinese Glioma Genome Atlas (CGGA) dataset. The DNA methylation levels of MIR155HG CpG islands were assessed through bisulfite amplicon sequencing (BSAS). The regulatory mechanism of SP1 on MIR155HG was examined by chromatin immunoprecipitation (ChIP) and luciferase reporter assays. R language was used as the main tool for statistical analysis and graphical work.

Results: MIR155HG was predominantly expressed in the isocitrate dehydrogenase (IDH) wild-type as well as mesenchymal subtype gliomas. Promoter methylation levels of MIR155HG in glioblastoma (GBM) were remarkably decreased compared with those in lower-grade glioma (LGG). In addition, there were negative correlations between promoter methylation levels and MIR155HG expressions but positive correlations with patients' overall survival. In vitro studies further revealed that MIR155HG expression was regulated by DNA promoter methylation and transcription factor (SP1) binding to the promoter. Moreover, there was a close association between MIR155HG expression and immune as well as stromal cell infiltrations, inflammatory activities, and immune checkpoints. Clinically, univariate and multivariate Cox analyses revealed that MIR155HG is an independent prognostic marker for glioma patients.

Conclusion: Our results established that MIR155HG is a potential biomarker for prognosis and an immunotherapeutic target in glioma.

Citing Articles

Integrative analysis of genomic and epigenomic regulation reveals miRNA mediated tumor heterogeneity and immune evasion in lower grade glioma.

Yang Z, Liu X, Xu H, Teschendorff A, Xu L, Li J Commun Biol. 2024; 7(1):824.

PMID: 38971948 PMC: 11227553. DOI: 10.1038/s42003-024-06488-9.

Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives.

Lin H, Liu C, Hu A, Zhang D, Yang H, Mao Y J Hematol Oncol. 2024; 17(1):31.

PMID: 38720342 PMC: 11077829. DOI: 10.1186/s13045-024-01544-7.

Zhu L, Yuan F, Wang X, Zhu R, Guo W Cancer Biomark. 2024; 40(2):185-198.

PMID: 38578883 PMC: 11307024. DOI: 10.3233/CBM-230341.

The landscape of immune checkpoint-related long non-coding RNAs core regulatory circuitry reveals implications for immunoregulation and immunotherapy responses.

Qu C, Cui H, Xiao S, Dong L, Lu Q, Zhang L Commun Biol. 2024; 7(1):327.

PMID: 38485995 PMC: 10940638. DOI: 10.1038/s42003-024-06004-z.

The prognostic value and immune landscaps of m6A/m5C-related lncRNAs signature in the low grade glioma.

Li R, Chen H, Li C, Qi Y, Zhao K, Wang J BMC Bioinformatics. 2023; 24(1):274.

PMID: 37403043 PMC: 10320943. DOI: 10.1186/s12859-023-05386-x.

References

Ren X, Han Y, Lin Q . Long non-coding RNA MIR155HG knockdown suppresses cell proliferation, migration and invasion in NSCLC by upregulating TP53INP1 directly targeted by miR-155-3p and miR-155-5p. Eur Rev Med Pharmacol Sci. 2020; 24(9):4822-4835. DOI: 10.26355/eurrev_202005_21171. View

Wu W, Yu T, Wu Y, Tian W, Zhang J, Wang Y . The miR155HG/miR-185/ANXA2 loop contributes to glioblastoma growth and progression. J Exp Clin Cancer Res. 2019; 38(1):133. PMC: 6427903. DOI: 10.1186/s13046-019-1132-0. View

Dong X, Deng Q, Nie X, Zhang M, Jia W, Chen C . Downregulation of HTATIP2 expression is associated with promoter methylation and poor prognosis in glioma. Exp Mol Pathol. 2015; 98(2):192-9. DOI: 10.1016/j.yexmp.2015.01.013. View

Wu X, Hou P, Qiu Y, Wang Q, Lu X . Large-Scale Analysis Reveals the Specific Clinical and Immune Features of DGCR5 in Glioma. Onco Targets Ther. 2020; 13:7531-7543. PMC: 7402863. DOI: 10.2147/OTT.S257050. View

Yu K, Yang H, Lv Q, Wang L, Tan Z, Zhang Z . Construction of a competitive endogenous RNA network and analysis of potential regulatory axis targets in glioblastoma. Cancer Cell Int. 2021; 21(1):102. PMC: 7881621. DOI: 10.1186/s12935-021-01789-z. View

Jain R, Tomaso E, Duda D, Loeffler J, Sorensen A, Batchelor T . Angiogenesis in brain tumours. Nat Rev Neurosci. 2007; 8(8):610-22. DOI: 10.1038/nrn2175. View

Wen P, Kesari S . Malignant gliomas in adults. N Engl J Med. 2008; 359(5):492-507. DOI: 10.1056/NEJMra0708126. View

Ruan Y, Ogana H, Gang E, Kim H, Kim Y . Wnt Signaling in the Tumor Microenvironment. Adv Exp Med Biol. 2020; 1270:107-121. PMC: 8477804. DOI: 10.1007/978-3-030-47189-7_7. View

Ribas A, Wolchok J . Cancer immunotherapy using checkpoint blockade. Science. 2018; 359(6382):1350-1355. PMC: 7391259. DOI: 10.1126/science.aar4060. View

10.

Wang W, Li J, Lin F, Guo J, Zhao J . Identification of N-methyladenosine-related lncRNAs for patients with primary glioblastoma. Neurosurg Rev. 2020; 44(1):463-470. DOI: 10.1007/s10143-020-01238-x. View

11.

Ye X, Xu S, Xin Y, Yu S, Ping Y, Chen L . Tumor-associated microglia/macrophages enhance the invasion of glioma stem-like cells via TGF-β1 signaling pathway. J Immunol. 2012; 189(1):444-53. DOI: 10.4049/jimmunol.1103248. View

12.

Zhu H, You Y, Shen Z, Shi L . EGFRvIII-CAR-T Cells with PD-1 Knockout Have Improved Anti-Glioma Activity. Pathol Oncol Res. 2020; 26(4):2135-2141. DOI: 10.1007/s12253-019-00759-1. View

13.

Lou Y, Diao L, Parra Cuentas E, Denning W, Chen L, Fan Y . Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma. Clin Cancer Res. 2016; 22(14):3630-42. PMC: 4947453. DOI: 10.1158/1078-0432.CCR-15-1434. View

14.

Patel S, Alam A, Pant R, Chattopadhyay S . Wnt Signaling and Its Significance Within the Tumor Microenvironment: Novel Therapeutic Insights. Front Immunol. 2020; 10:2872. PMC: 6927425. DOI: 10.3389/fimmu.2019.02872. View

15.

He X, Sheng J, Yu W, Wang K, Zhu S, Liu Q . LncRNA MIR155HG Promotes Temozolomide Resistance by Activating the Wnt/β-Catenin Pathway Via Binding to PTBP1 in Glioma. Cell Mol Neurobiol. 2020; 41(6):1271-1284. PMC: 11448642. DOI: 10.1007/s10571-020-00898-z. View

16.

Buckner J, Brown P, ONeill B, Meyer F, Wetmore C, Uhm J . Central nervous system tumors. Mayo Clin Proc. 2007; 82(10):1271-86. DOI: 10.4065/82.10.1271. View

17.

Su J, Ma Q, Long W, Tang H, Wu C, Luo M . Is a Prognostic Biomarker and Correlates With Stromal and Immune Infiltration in Gliomas. Front Oncol. 2019; 9:1083. PMC: 6803540. DOI: 10.3389/fonc.2019.01083. View

18.

He Y, Ye Y, Tian W, Qiu H . A Novel lncRNA Panel Related to Ferroptosis, Tumor Progression, and Microenvironment is a Robust Prognostic Indicator for Glioma Patients. Front Cell Dev Biol. 2021; 9:788451. PMC: 8691457. DOI: 10.3389/fcell.2021.788451. View

19.

Quail D, Bowman R, Akkari L, Quick M, Schuhmacher A, Huse J . The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas. Science. 2016; 352(6288):aad3018. PMC: 5450629. DOI: 10.1126/science.aad3018. View

20.

Peng L, Chen Z, Chen Y, Wang X, Tang N . MIR155HG is a prognostic biomarker and associated with immune infiltration and immune checkpoint molecules expression in multiple cancers. Cancer Med. 2019; 8(17):7161-7173. PMC: 6885872. DOI: 10.1002/cam4.2583. View